Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NIAID Centralized Sequencing Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03206099
Recruitment Status : Recruiting
First Posted : July 2, 2017
Last Update Posted : July 29, 2022
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:

Background:

Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.

Objective:

To understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.

Eligibility:

Participants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives

Design:

Researchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.

Participants will receive results that:

  • Are important to their health
  • Have been confirmed in a clinical lab
  • Suggest that they could be at risk for serious disease that may affect your current or future medical management.

Some genetic information we return to participants may be of uncertain importance.

If genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report:

  • Normal variants
  • Information about progressive, fatal conditions that have no effective treatment
  • Carrier status (conditions you don t have but could pass on)

The samples and data will be saved for future research.

Personal data will be kept as private as possible.

If future studies need new information, participants may be contacted.


Condition or disease
Atopy Primary Immunodeficiency Autoimmunity Autoinflammation

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Family-Based
Time Perspective: Prospective
Official Title: NIAID Centralized Sequencing Protocol
Actual Study Start Date : July 31, 2017
Estimated Primary Completion Date : December 31, 2029
Estimated Study Completion Date : December 31, 2029


Group/Cohort
Biological relatives
Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
Healthy volunteers
Select internal controls
Probands
Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.



Primary Outcome Measures :
  1. Identifying novel genetic defects associated with immune disorders [ Time Frame: Upon analysis of genomic data ]
    Identifying novel genetic defects associated with immune disorders

  2. Identifying novel clinical phenotypes associated with established genetic defects [ Time Frame: Upon analysis of genomic data ]
    Identifying novel clinical phenotypes associated with established genetic defects

  3. Identifying established genetic disorders of the immune system [ Time Frame: Upon analysis of genomic data ]
    Identifying established genetic disorders of the immune system, as well as known genetic disorders outside of the immune system in some cases


Secondary Outcome Measures :
  1. Evidence base for how to improve clinical genomic services on this protocol and related programs. [ Time Frame: 5.1.1. Enrollment/Baseline Report Comprehension Survey and Semi-Structured Phone Interviews ]
    Studies of the processes and outcomes of the clinical genomics and genetic counseling services performed under this protocol. These studies will use surveys, interviews, and other social and behavioral research methods to collect data from study participants about their perceptions, experiences, and attitudes related to their condition and participation in this protocol. The goal of these additional studies will be to improve the services provided under protocol 17-I-0122 and to generate an evidence base for other investigators conducting similar studies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Day and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Probands and their biological relatives (primarily clinical), recruited from NIAID protocols (both at the NIH and CNHS).
Criteria
  • PARTICIPANT INCLUSION CRITERIA:
  • Must fulfill one of the following criteria:

    • Proband participants: must have a disease under investigation by another NIH protocol on which they are co-enrolled.
    • Biological relatives: biologically related to a proband participant, and does not have a disease under investigation in another NIH protocol.
    • Healthy volunteers: unrelated to a proband participant, and does not have a disease under investigation in another NIH protocol.
  • Aged 0-99 years.
  • Participants must be willing to undergo genetic testing.
  • Participants must be willing to allow samples to be stored for future research.
  • Participants must be willing to have their de-identified genomic data shared, for example in a controlled access databases like the Database of Genotypes and Phenotypes (dbGaP).
  • Adult healthy volunteers must be able to provide informed consent.

PARTICIPANT EXCLUSION CRITERIA:

Any condition that, in the opinion of the investigator, contraindicates participation in this study is a reason for exclusion.

Co-enrollment guidelines:

Probands must be enrolled on another NIH - either at the NIH CC or CNHS - protocol as their primary protocol for carrying out clinical and research evaluations. Relatives of probands may be enrolled in this protocol whether or not the relatives are enrolled on another NIH protocol. However, we may prioritize enrolling relatives who are on other NIH protocols and have undergone careful phenotyping on those protocols. Careful phenotyping is important, even for participants who are apparently healthy. Because the primary research team is best suited to characterize their participants phenotypes, phenotyping of co-enrolled relatives will be performed on the primary protocols.

SUBSTUDY INCLUSION CRITERIA:

  • Aged 14-99 years.
  • English language proficiency.
  • Ability to provide informed consent.

SUBSTUDY EXCLUSION CRITERIA:

  • Have received positive genetic results from this protocol in the past.
  • Any condition that, in the opinion of the investigator, contraindicates participation in this substudy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03206099


Contacts
Layout table for location contacts
Contact: Morgan N Similuk (301) 435-6691 morgan.similuk@nih.gov

Locations
Layout table for location information
United States, District of Columbia
Children's National Health System Recruiting
Washington, District of Columbia, United States, 20010
Contact: Vanessa Bundy    202-476-3016    vbundy2@cnmc.org   
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY dial 711    ccopr@nih.gov   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: Morgan N Similuk National Institute of Allergy and Infectious Diseases (NIAID)
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT03206099    
Other Study ID Numbers: 170122
17-I-0122
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: July 29, 2022
Last Verified: July 26, 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Phenotyping
Genetics
Sequencing
Inborn Errors of Immunity
Genomics
Natural History
Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Immunodeficiency Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Genetic Diseases, Inborn